Ökkeş Zortuk, Cihan Bedel, Günay Yıldız, Fatih Selvi, Yusuf Karancı
{"title":"EASIX as a new predictor of mortality in cerebrovascular diseases.","authors":"Ökkeş Zortuk, Cihan Bedel, Günay Yıldız, Fatih Selvi, Yusuf Karancı","doi":"10.1093/labmed/lmaf082","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Cerebrovascular disease (CVD) represents a major global health concern that affects the blood vessels throughout the body and contributes to a considerable burden of mortality and morbidity. The Endothelial Activation and Stress Index (EASIX) has recently emerged as a promising biomarker for predicting many disease complications and outcomes. We aimed to investigate the relationship between EASIX and disease mortality in patients with CVD.</p><p><strong>Methods: </strong>The present study was conducted in a tertiary emergency department between January 6, 2023, and January 6, 2024, who were diagnosed with CVD. The mortality rate among patients within a 1-month period was analyzed. The EASIX was calculated using lactate dehydrogenase level (U/L) × creatinine level (mg/dL)/platelet count (×109/L). The parameters were then compared in relation to disease morbidity.</p><p><strong>Results: </strong>Following the exclusion of patients who met the preestablished exclusion criteria, the study included 74 participants. In the 1-month follow-up of 64 patients, no mortality was observed. The median EASIX score was 0.80 (IQR, 0.5-2.2) in the surviving patients, while the median EASIX score was 2.90 (IQR, 1.00-10.55) in the patients who died, indicating a statistically significantly higher score (P < .001).</p><p><strong>Discussion: </strong>EASIX has the potential to be a prognostic marker for mortality in patients with CVD.</p>","PeriodicalId":94124,"journal":{"name":"Laboratory medicine","volume":"57 2","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Laboratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/labmed/lmaf082","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Cerebrovascular disease (CVD) represents a major global health concern that affects the blood vessels throughout the body and contributes to a considerable burden of mortality and morbidity. The Endothelial Activation and Stress Index (EASIX) has recently emerged as a promising biomarker for predicting many disease complications and outcomes. We aimed to investigate the relationship between EASIX and disease mortality in patients with CVD.
Methods: The present study was conducted in a tertiary emergency department between January 6, 2023, and January 6, 2024, who were diagnosed with CVD. The mortality rate among patients within a 1-month period was analyzed. The EASIX was calculated using lactate dehydrogenase level (U/L) × creatinine level (mg/dL)/platelet count (×109/L). The parameters were then compared in relation to disease morbidity.
Results: Following the exclusion of patients who met the preestablished exclusion criteria, the study included 74 participants. In the 1-month follow-up of 64 patients, no mortality was observed. The median EASIX score was 0.80 (IQR, 0.5-2.2) in the surviving patients, while the median EASIX score was 2.90 (IQR, 1.00-10.55) in the patients who died, indicating a statistically significantly higher score (P < .001).
Discussion: EASIX has the potential to be a prognostic marker for mortality in patients with CVD.